Wake Forest University School Of Medicine News
Most Popular Wake Forest University School Of Medicine Story
ALSO NOTED: ImaRx prices IPO; Sepracor, Eisai sign deal for Lunesta; and much more...
> GSK has decided not to exercise its option to license Exelixis' non-small cell lung cancer drug XL647 for further development. Read more...
Latest Headlines
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
